Michael E. Wechsler, MD, a pulmonologist at National Jewish Health, discusses the challenges associated with differentiating similar eosinophilic conditions, including eosinophilic asthma, from one another.
Michael E. Wechsler, MD, a pulmonologist at National Jewish Health, discusses the challenges associated with differentiating similar eosinophilic conditions, including eosinophilic asthma, from one another.
Transcript
What are some of the challenges with distinguishing eosinophilic asthma from other diagnoses associated with abnormal eosinophil activity?
Well, you have to recognize that eosinophils are involved, and you can do that easily by evaluating the number of eosinophils in the blood. And so, with any disease state, you want to look for eosinophils at or in the tissue. And there aren't major challenges in terms of distinguishing from other eosinophilic conditions, other than the fact that there can be some overlap between the different conditions.
So for instance, there's eosinophilic asthma, that's basically just airway disease with eosinophils in the blood and/or the airway. Then, there's an entity called chronic eosinophilic pneumonia, which is basically eosinophilic asthma with some chronic sinus disease and pulmonary infiltrates. And then there is an entity called EGPA, or eosinophilic granulomatosis with polyangiitis. And that's an entity that's characterized by asthma, eosinophilia, sinus disease, pulmonary infiltrates, and then vasculitis in 1 or more end organ, including in neuropathy. And lastly, there are hypereosinophilic syndromes, which aren't really associated with asthma but have eosinophilia and organ involvement in systemic manifestations.
Early Detection Strategies for Interstitial Lung Disease in Rheumatology: Janet Pope, MD, MPH
August 11th 2025Janet Pope, MD, MPH, discusses screening and diagnostic approaches for interstitial lung disease in patients with systemic sclerosis, rheumatoid arthritis, and other connective tissue diseases.
Read More
Hope on the Horizon for Underserved Patients With Multiple Myeloma: Joseph Mikhael, MD
August 12th 2025Explore the disparities in multiple myeloma treatment and how new initiatives aim to improve clinical trial participation among underrepresented patients during a conversation with Joseph Mikhael, MD, MEd, FRCPC, FACP, FASCO, chief medical officer of the International Myeloma Foundation.
Listen
AI Meets Medicare: Inside CMS’s WISeR Model With Sanjay Doddamani, MD, MBA, Part 2
August 5th 2025In this second part of his interview with The American Journal of Managed Care®, Sanjay Doddamani, MD, MBA, a former senior advisor to CMMI and founder and CEO of Guidehealth, continues a dialogue on the future of value-based care and the promise—and limits—of AI-enabled innovation, reflecting on challenges like rising Medicare costs and patients’ growing financial burdens.
Read More